More news today. Volume is up, although the price is down.
Aethlon Medical Submits for NIH Cancer Research Grant
Last Update: 4/11/2006 9:34:19 AM Data provided by
SAN DIEGO, Apr 11, 2006 (BUSINESS WIRE) -- Aethlon Medical, Inc. (AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that it has submitted a cancer research grant application entitled "Tumor Exosome Removal to Stimulate Cancer-Specific Immunity." The grant was submitted to the National Institute of Health (NIH) and directed to the National Cancer Institute as a Phase I Small Business Innovation Grant. A review and formal response to the grant application is expected from the NIH in August. The grant application discusses the potential use of the Aethlon Hemopurifier(TM )as a method to remove exosomes that suppress the immune response in cancer patients. Significant levels of immune-suppressive exosomes are identified in cancer patients, whereas healthy individuals maintain negligible levels. Aethlon proposes to improve the immune response to malignancies by reducing the presence of tumor-derived exosomes, thereby activating immunity to cancers. There is no assurance that Aethlon will derive grant income related to this research initiative.
About Aethlon Medical
Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
SOURCE: Aethlon Medical, Inc.